Astrazeneca to Invest $15 Billion in China Through 2030

MT Newswires Live01-29

Astrazeneca (AZN) said Thursday it plans to invest $15 billion in China through 2030 on manufacturing of medicine, and research and development.

The investment will support drug discovery, clinical development and manufacturing in China, while improving cell therapy and radioconjugates capabilities.

Astrazeneca said the investment will create thousands of new jobs and grow its workforce in China to more than 20,000 employees.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment